tiprankstipranks

Spectrum announces Rolvedon added to latest NCCN Guidelines

Spectrum announced that Rolvedon has been added to the latest National Comprehensive Cancer Network Supportive Care Guidelines, or NCCN Guidelines, in oncology for Hematopoietic Growth Factors. The NCCN Guidelines provide recommendations for the appropriate use of growth factors in the clinical management of febrile neutropenia and now include Rolvedon as a treatment option under Management of Neutropenia: G-CSFs for Prophylaxis of Febrile Neutropenia and Maintenance of Scheduled Dose Delivery.

Confident Investing Starts Here:

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on SPPI:

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue